AbbVie Completes Acquisition of Landos Biopharma

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)

Read more at prnewswire.com